It was referred to the National Assembly's Health and Welfare Committee as the number of people's consent to the application of breast cancer treatment Enhertu's health insurance reached 50,000. Enhertu is an antibody-drug conjugate that obtained a domestic marketing license last year due to the petition of the National Assembly. The petition for the approval of Enhertu Health Insurance rose on the 30th of last month, and 50,000 people agreed on the 3rd of this month, five days later. The petitioner pointed out that Enhertu is a high-priced drug that costs 5 million won per injection, and expressed the need to strengthen the accessibility of breast cancer patients.

In June and August last year, Enhertu